Gain-of-function mutations in NOTCH1 are common in T-cell lymphoblastic leukemias and lymphomas (T-ALL), making this receptor a promising target for drugs such as c-secretase inhibitors, which block a proteolytic cleavage required for NOTCH1 activation. However, the enthusiasm for these therapies has been tempered by tumor resistance and the paucity of information on the oncogenic programs regulated by oncogenic NOTCH1. Here we show that NOTCH1 regulates the expression of PTEN (encoding phosphatase and tensin homolog) and the activity of the phosphoinositol-3 kinase (PI3K)-AKT signaling pathway in normal and leukemic T cells. Notch signaling and the PI3K-AKT pathway synergize in vivo in a Drosophila melanogaster model of Notch-induced tumorigenesis, and mutational loss of PTEN is associated with human T-ALL resistance to pharmacological inhibition of NOTCH1. Overall, these findings identify transcriptional control of PTEN and regulation of the PI3K-AKT pathway as key elements of the leukemogenic program activated by NOTCH1 and provide the basis for the design of new therapeutic strategies for T-ALL.
NOTCH receptors at the cell surface directly transform extracellular signals into changes in gene expression that regulate differentiation, self renewal, proliferation and apoptosis 1 . Constitutively active forms of the NOTCH1 receptor contribute to over 50% of human T-ALL 2 , and have also been implicated in the pathogenesis of solid tumors, such as breast carcinomas, gliomas and neuroblastoma [3] [4] [5] . NOTCH1 signaling, whether initiated by receptor-ligand interactions or triggered by mutations in the NOTCH1 gene, requires two consecutive proteolytic cleavages of the receptor, the first by an ADAM (a disintegrin and metalloprotease) metalloprotease and the second by a g-secretase complex [6] [7] [8] [9] . The final cleavage releases intracellular NOTCH1 from the membrane, allowing it to translocate into the nucleus and interact with members of the CBF1-RBP-Jk-suppressor of hairless-LAG-1 (CSL) DNA-binding protein family to activate the expression of target genes 10, 11 . The high prevalence of activating mutations in NOTCH1 in T-ALL 2 and the availability of smallmolecule inhibitors of g-secretase (GSIs) capable of blocking NOTCH1 activation have prompted clinical trials to test the effectiveness of these agents against T-ALL. However, the efficacy of this strategy has been questioned, as GSIs seem to be active in only a small fraction of T-ALL cell lines with constitutive NOTCH1 activity 2 .
RESULTS

PTEN mutations in GSI-resistant T-ALL cells
To elucidate the mechanism of GSI resistance in T-ALL, we tested the ability of a well-characterized GSI, Compound E (ref. 12) , to inhibit NOTCH1 processing and signaling in a panel of T-ALL cell lines that harbor prototypical activating mutations in NOTCH1 (Supplementary Table 1 online) and have been previously characterized for their response to this GSI 2, 13 . Both GSI-sensitive (ALL-SIL, CUTLL1, DND41, HPB-ALL and KOPTK1) and GSI-resistant (CCRF-CEM, P12-ICHIKAWA, PF382, MOLT3 and RPMI8402) cell lines showed NOTCH1 inhibition when treated with Compound E (Supplementary Figs. 1 and 2 online), leading us to speculate that resistance to GSI action may be mediated by molecular abnormalities in signaling pathways that promote cell growth downstream of NOTCH1. To test this hypothesis, we used oligonucleotide microarrays to identify differentially expressed genes associated with GSI sensitivity or resistance within this panel of well-characterized GSI-sensitive and GSIresistant cell lines. Nearest-neighbor analysis using the signal-to-noise statistic identified PTEN, which encodes a key tumor suppressor that inhibits the PI3K-AKT signaling pathway 14 , as the gene most consistently downregulated in GSI-resistant cell lines (Fig. 1a) .
Western blot analysis showed readily detectable PTEN protein in all GSI-sensitive T-ALL cells, but PTEN was either absent or markedly decreased in all five GSI-resistant cell lines analyzed (Fig. 1b) . Further analysis demonstrated that each of the five GSI-resistant cell lines harbored mutations in PTEN, whereas the five GSI-sensitive cell lines expressed normal PTEN transcripts (Supplementary Table 2 online) . PTEN mutations associated with GSI resistance typically were homozygous and encode premature stop codons that resulted in truncated PTEN protein products. Only RPMI8402 cells contained both a truncating mutation in PTEN and a missense mutation (R159S) in the phosphatase domain in the other allele, which was consistent with the presence of detectable PTEN protein in this cell line and with its variable response to GSI 2 .
PTEN mutations are frequent in solid tumors, and loss of PTEN has been shown to promote the self-renewal of leukemic stem cells 15 . Furthermore, PTEN deficiency has been proposed to have a role in the pathogenesis of T-cell tumors on the basis of studies in Pten knockout mice [16] [17] [18] [19] [20] . However, PTEN mutations have only been reported sporadically in human leukemias and lymphomas [21] [22] [23] . Thus, to determine whether our discovery of PTEN loss in GSI-resistant cell lines might also be relevant to primary human cancers, we examined the status of PTEN in T-ALL clinical samples. We found loss of the PTEN protein (as determined by immunohistochemistry) in 6 of 35 (17%) T-ALL samples, including one relapsed sample in a lymphoma case that was PTEN-positive at diagnosis (Fig. 1c and Supplementary Table 3 online). In addition, flow cytometry analysis of PTEN expression in primary T-ALL samples showed loss of PTEN protein in 3 of 18 (17%) cases, in perfect accordance with our immunohistochemistry results (data not shown). Sequence analysis showed mutations in PTEN in 9 of 111 (8%) T-ALL cases at diagnosis (Fig. 1d) . In addition, one sample expressed the PTEN pseudogene with no expression of normal PTENP1 transcripts (Supplementary Table 4 online). We have shown before that aberrant expression of transcription factor oncogenes involved in the pathogenesis of T-cell tumors, such as TAL1, TLX1, TLX3, LYL1, LMO1 and LMO2, define distinct molecular, biological and clinical groups of T-ALLs 24, 25 . PTEN mutations were found in samples with aberrant expression of TLX3, TAL1, LYL1 and LMO2, and no particular association of PTEN mutation with the expression of any of these T-ALL transcription factor oncogenes was noted. Subsequent analysis of 35 paired samples of DNA from T-ALL lymphoblasts collected at diagnosis and at relapse showed two additional PTEN mutant cases in which loss of this tumorsuppressor gene occurred during disease progression (Supplementary Table 5 online). Notably, although NOTCH1 mutations and PTEN loss can occur independently in the pathogenesis of T-ALL, at least four of the PTEN-mutated samples identified in this series harbored concomitant mutations in NOTCH1 (Supplementary  Tables 4 and 5) . Overall these results demonstrate that PTEN mutations and loss of PTEN protein expression are highly frequent in T-ALL cell lines, occur in a subset of human T-cell leukemias and lymphomas at diagnosis and can also be found as a secondary event during disease progression.
Aberrant AKT signaling induces resistance to GSI How might PTEN mutations in T-ALL lymphoblasts confer resistance to NOTCH1 inhibition by GSIs? As a critical regulator of the PI3K-AKT signal transduction pathway, PTEN controls multiple cellular responses, including metabolic regulation and cell growth and survival 26 . Activation of PI3K by extracellular stimuli generates phosphatidylinositol triphosphate (PIP3) in the plasma membrane. PIP3 recruits the AKT kinase to the membrane, where it is phosphorylated and activated by phosphatidylinositol-dependent kinase-1 (ref. 26) . Upon its activation, AKT triggers the phosphorylation of numerous protein targets, such as the mTOR kinase, and influences multiple cellular processes including cell growth and proliferation 26 . The PTEN gene encodes a lipid phosphatase that is responsible for PIP3 dephosphorylation and clearance and is required to switch off AKT activation 26, 27 . To pursue this putative link between PTEN and the PI3K-AKT pathway in T-ALL, we examined the levels of AKT phosphorylation in our panel of GSI-sensitive, PTEN-positive and GSI-resistant, PTEN-null cell lines. Western blot analysis showed that the abundance of p-AKT (phosphorylated on Ser473) were low and inversely correlated with PTEN expression in GSI-sensitive, PTENpositive T-ALL cells (Fig. 1b) . In contrast, GSI-resistant, PTEN-null T-ALL samples had high levels of AKT phosphorylation, indicative of constitutive activation of the PI3K-AKT signaling pathway.
To test the prediction that unrestrained activation of the PI3K-AKT signaling pathway causes T-ALL resistance to GSIs, we expressed a constitutively active myristoylated form of AKT (MYR-AKT) in the GSI-sensitive CUTLL1 cell line. Inhibition of NOTCH1 signaling by Compound E treatment typically impaired the growth of CUTLL1 cells ( Fig. 2a) , whereas enforced MYR-AKT expression induced constitutive phosphorylation of AKT ( Supplementary Fig. 3 online), which was sufficient to rescue these cells from the growth-inhibitory effects of NOTCH1 inhibition by GSI (Fig. 2a,b) . Similarly, shRNA knockdown of PTEN in DND41 cells ( Supplementary Fig. 3 ) blocked the cell growthinhibitory effects of Compound E in this GSI-sensitive, PTEN-positive cell line (Fig. 2c,d ). Together, these results indicate that aberrant activation of the PI3K-AKT signaling pathway induces resistance to NOTCH1 inhibition in T-ALL cells.
NOTCH1 regulates PTEN and the PI3K-AKT pathway
The close association between PTEN mutation and GSI resistance in T-ALL prompted us to ask whether PTEN might be functionally linked to NOTCH1 signaling. Analysis of the transcriptional responses of GSI-sensitive, PTEN-positive cells to NOTCH1 inhibition showed significant upregulation of PTEN expression ( Fig. 3a , P o 0.01), with consequently higher PTEN protein levels, and gradual inhibition of the PI3K-AKT pathway, as judged by decreased Ser473 phosphorylation on AKT (Fig. 3b) .
Ligand-mediated activation of NOTCH signaling during T-cell development is required to maintain cell growth and glucose metabolism at the time of T-cell receptor b-chain selection and has been associated with increased AKT phosphorylation 28 . However, the mechanism responsible for PI3K-AKT upregulation downstream of NOTCH activation during normal thymocyte development remains unknown. We therefore hypothesized that transcriptional downregulation of PTEN could mediate the upregulation of the PI3K-AKT signaling pathway, not only in T-ALL cells but also in developing thymocytes. To test this hypothesis, we analyzed the effects of withdrawing NOTCH1 signals, driven by the NOTCH1 ligand Delta-like 1 (DL1), from T-cell precursors. Immature CD4 -CD8 -double-negative 3 (DN3) thymocytes were generated by coculture of hematopoietic progenitors from Rag -/-mice with stromal cells expressing DL1 (OP9-DL1 cells). Purified DN3 cells were subsequently cultured in the presence of continuous Notch1 signaling by coculture with OP9-DL1 cells, or they were deprived of DL1 stimulation of Notch1 by coculture with regular OP9 stromal cells. Loss of Notch1 signaling in the DN3 thymocytes cultured with OP9 cells induced marked downregulation of the Notch1 target gene Hes1 (hairy and enhancer-of-split homolog) at day 1 and progressive upregulation of Pten transcript levels, as compared to DN3 cells maintained in culture with OP9-DL1 cells (Fig. 3c ). These results demonstrate that the regulation of PTEN expression downstream of NOTCH1 is not limited to human T-ALL cells harboring oncogenic NOTCH1 alleles, as it is also present in normal mouse thymocytes upon activation of the wild-type Notch1 receptor by DL1.
Detailed phenotypic analysis of cellular responses to NOTCH1 inhibition in T-ALL showed that blocking NOTCH1 signaling with shRNA knockdown or GSI treatment in PTEN-positive T-ALL cells induced cellular responses typically associated with inhibition of the PI3K-AKT signaling pathway, such as decreased cell size (Fig. 2a,c) , reduced glucose metabolism (Fig. 3d,e ) and increased autophagy ( Supplementary Fig. 4 online) . Analysis of glucose use in GSI-sensitive, PTEN-positive HPB-ALL cells showed significant reductions in glucose uptake and glucose oxidation upon NOTCH1 inhibition (Fig. 3d,e) , and increased levels of glucose uptake and glucose oxidation in GSIresistant, PTEN-null P12-ICHIKAWA cells (Fig. 3f,g ), whose glucose metabolism was not affected by GSI treatment (Fig. 3d,e) . These results suggest that a NOTCH1-PTEN-AKT regulatory axis mediates the physiologic upregulation of the PI3K-AKT signaling pathway during normal thymocyte development, whereas aberrant NOTCH1 signaling in T-ALL converts this developmental transcriptional network to a mechanism that promotes leukemic cell growth.
HES1 and MYC regulate PTEN downstream of NOTCH1
The inhibitory effect of NOTCH1 signaling on PTEN expression conflicts with the well-established role of NOTCH1 as transcriptional activator. Thus, we considered that inhibition of PTEN by NOTCH1 could be mediated by HES1 and MYC, two transcription factors directly controlled by NOTCH1 (refs. 29-32) . Chromosome immunoprecipitation (ChIP)-on-chip analysis of promoter occupancy by HES1, MYC and NOTCH1 in the HPB-ALL leukemic cell line showed binding of both MYC and HES1 to regulatory sequences in the PTEN proximal promoter ( Supplementary Fig. 5 online) , a result that was fully validated by quantitative ChIP assays (Fig. 4a,b) . HES1 bound in the vicinity of the PTEN transcription initiation site, whereas MYC occupied at least two regulatory regions located around positions -1,400 and -500 base pairs (bp) upstream of the PTEN gene, as well as the region occupied by HES1, 200 bp downstream from the PTEN transcription initiation site.
The functional significance of HES1 and MYC binding to the PTEN promoter was demonstrated in luciferase reporter assays, which showed that HES1 expression induced a marked reduction (86%) in the luciferase activity of a 3-kilobase construct that encodes the luciferase gene under control of the PTEN promoter, whereas MYC expression resulted in a substantial increase in luciferase expression (334% over basal levels) (Fig. 4c) . Reporter assays performed with deletion constructs of the PTEN promoter demonstrated redundancy of regulatory sequences occupied by MYC in the activity of PTEN reporter constructs and confirmed the dominant role of HES1 as negative regulator of the PTEN promoter (data not shown). Furthermore, shRNA knockdown of HES1 induced transcriptional upregulation of PTEN in T-ALL cells (Fig. 4d) . These findings are in agreement with the analysis of Hes1-knockout mice, which showed an essential role for this transcriptional repressor in promoting cell growth and proliferation during thymocyte development downstream of Notch1 (ref. 33 ).
Synergistic effect of Notch and PI3K-AKT in Drosophila
We have established a highly specific forward genetic screen in Drosophila that searches for genes that functionally cooperate with the Notch pathway and that convert tissue overgrowths into tumors 34, 35 . The observation that mutational loss of PTEN sustains cell growth in T-ALL even when NOTCH1 signaling is inhibited was further reinforced by the independent identification of a close relationship between Notch and Akt1 during tumorigenesis in this model ( Fig. 5 and Supplementary Figs. 6-8 online) .
We used a Drosophila strain that overexpressed the Notch ligand Delta, which caused a 'large eye' phenotype due to overgrowth 36 (Fig. 5b) ; this strain was used in conjunction with the Gene Search method to systematically generate 'gain-of-expression' mutations 34, 35 . In this screen we identified a GS line, 1D233C, that enforced expression of the Akt1 gene ( Supplementary Fig. 6a online) and that, when coupled to Delta overexpression, produced massive overgrowths and tumors (Fig. 5c,d and Supplementary Fig. 6d online) that led to disseminated eye-derived secondary growths inside the thorax and abdomen in about 7.14% of the flies (n ¼ 232, Fig. 5d ). Eye overgrowths and secondary eye growths were also observed, albeit to a lesser degree (2.22%, n ¼ 323), in flies with Delta overexpression combined with a transgene encoding the Drosophila phosphatidylinositol-3-OH kinase 92E (also known as Dp110) ( Supplementary  Fig. 6b-c and Supplementary Fig. 7 online) . Eye growth was tightly associated with levels of p-Akt1 (phosphorylated on Ser505). Thus, Akt1 phosphorylation was found to be increased in the eye imaginal discs overexpressing Delta ('large eye') and even more markedly augmented in the eye imaginal discs that overexpressed both Delta and Akt1 (eye overgrowth and tumor phenotype) ( Supplementary  Fig. 8a-d online) . Pharmacological inhibition of Notch receptor proteolysis with a GSI (DAPT) prevented eye growth induced by Delta overexpression and resulted in a small-eye defect ( Fig. 5e and Supplementary Fig. 9 online) , recapitulating the defective growth phenotype of PTEN-positive T-ALL cells treated with GSIs. Notably, a similar small-eye phenotype was induced upon overexpression of Pten, indicating that inhibition of Akt1 phosphorylation can block the growth-promoting effects of Notch hyperactivation (Fig. 5f) .
Moreover, loss of Akt1 (analyzed in genetic mosaics using an Akt1 q null allele, Supplementary Fig. 6e -j online) also blocked Deltainduced eye overgrowth. In contrast to previous reports, we found that inactivation of Akt1 does affect cell number (see Supplementary  Fig. 6e-g,j online) , suggesting that, as in its mammalian counterpart, Drosophila Akt1 positively regulates cell-cycle progression.
Consistently, the enforced expression of Akt1 by use of the GS1D233C cell line ( Supplementary Fig. 6a online) fully rescued the growth and cell-proliferation arrest caused by a reduction of Notch signaling owing to aberrant receptor glycosylation induced by generalized expression of the fringe gene (fng) [36] [37] [38] (Fig. 5g-h) , recapitulating the restoration of cell growth induced by constitutively active AKT expression in GSI-sensitive, PTEN-positive T-ALL cells treated with Supplementary Fig. 9 online) . (f) Gain of Pten results in strong suppression of Delta-mediated eye overgrowth (46% of ey-Gal44Dl sibling eye size) (n 4 160). (g) Overexpression of fringe (UAS-fng), a Notch pathway modulator, results in Notch inhibition in the eye and hence a small eye defect (5-13% of wild-type eye size). (h) Gain of expression of the Akt1 gene on the GS1D233C P-element fully rescued the growth defect caused by reducing Notch pathway activation (95-106% of wild-type eye size) (see also Supplementary Figs. 6 and 7) . Compound E and the resistant-to-GSI-treatment phenotype of PTEN-null T-ALL cell lines ( Figs. 1 and 2) . Together, these results demonstrate that activation of Akt1 restores the stoppage of cell growth and proliferation that occurs upon Notch inhibition and that aberrant Akt1 activity synergizes with Notch hyperactivation to promote tumor development in vivo.
Secondary oncogene addiction in PTEN-null T-ALL cells
The concept of oncogene addiction refers to the requirement for sustained high levels of oncogene signaling to maintain the viability of tumor cells. This explains the requirement for continuous NOTCH1 signaling in T-ALLs with activating mutations in NOTCH1. Notably, PTEN-deficient tumors have been shown to be hypersensitive to inhibition of the PI3K signaling pathway 39, 40 , and reintroduction of PTEN into the GSI-resistant, PTEN-null Jurkat T-cell leukemia cell line has been shown to induce cell cycle arrest and apoptosis and decrease cell size 41 . Because our data showed that loss of PTEN in T-ALL cells may result in resistance to GSI-mediated NOTCH1 inhibition, we hypothesized that GSI-resistance could occur at the expense of inducing an oncogene addiction switch from NOTCH1 (primary oncogene addiction) to constitutive AKT signaling (secondary oncogene addiction) (Fig. 6a) . Treatment of GSI-sensitive, PTEN-positive and GSIresistant, PTEN-null T-ALL cells with SH6, a phosphatidylinositol analog inhibitor of AKT, showed that pharmacologic inhibition of AKT has strong antileukemic effects in GSI-resistant, PTEN-null T-ALLs but not in GSI-sensitive, PTEN-positive cells (Fig. 6b) . Similarly, retroviral expression of PTEN in GSI-resistant T-ALL cells induced a marked reduction in cell size and G1 cell-cycle arrest ( Supplementary  Fig. 10 online) . Thus, in a clear example of secondary oncogene addiction, aberrant activation of the PI3K-AKT pathway makes PTEN-null T-ALL cells dependent on constitutive AKT signaling for maintenance of the malignant phenotype.
DISCUSSION
Targeted therapies for human tumors rely on the addiction of cancer cells to oncogenic signals driving tumor cell growth proliferation and survival 42, 43 . The NOTCH1 signaling pathway is a critical controller of cell fate decisions and is a key regulator of cell growth and metabolism during T-cell development and transformation. Notably, Notch signals regulate the trophic state (cell size, glucose uptake and glycolysis) of T-cell precursors through activation of the PI3K-Akt signaling pathway 28 . Here, we show that NOTCH1 controls a transcriptional network that regulates PTEN expression and PI3K-AKT signaling activity in normal thymocytes and in leukemic T cells. Similarly, Notch signaling and the PI3K-AKT pathway synergize in vivo in a Drosophila model of Notch-induced tumorigenesis. Importantly, activation of Akt reverses a cell-growth defect phenotype induced by the loss of Notch signaling in this model. Similarly, mutational loss of PTEN and the consequent hyperactivation of AKT is associated with resistance to NOTCH1 inhibition in human T-ALL. Overall, these findings suggest that the regulatory circuit linking NOTCH1 signaling with PTEN expression and PI3K-AKT activity may contribute to NOTCH1-induced transformation and could mediate, at least in part, the cellular response to NOTCH1 inhibitors in T-ALL. According to this model, mutational loss of PTEN in T-ALL would turn this moderate and tightly controlled upregulation of PI3K-AKT downstream of NOTCH1 into an aberrant and constitutively active oncogenic signal that would support cell growth and metabolism independently of NOTCH1 in PTEN-null T-ALL cells treated with GSIs (Fig. 6a) . Finally, our data show that, by bypassing the requirement for aberrant NOTCH1 signaling in leukemic cell growth, mutational loss of PTEN induces an oncogene addiction switch that renders T-ALL cells addicted to constitutively active AKT signaling.
Our results warrant further studies to test the efficacy of combined PI3K-AKT-and NOTCH1-directed therapies in human cancer.
METHODS
DNA microarray analysis. We extracted RNA from duplicate cultures of GSI-sensitive (ALL-SIL, CUTLL1, DND41, HPB-ALL, KOPTK1) and GSIresistant (CCRF-CEM, MOLT3, P12 ICHIKAWA, PF382 and RPMI8402) T-ALL cell lines treated for 24 h with vehicle (DMSO) or 500 nM Compound E and prepared samples for analysis with Affymetrix Human U133 Plus 2.0 arrays according to the manufacturer's instructions as previously described 44 . Interarray intensity differences were normalized with Dchip 45 . To establish the correlation of expression data between GSI-sensitive (class 0) and GSI-resistant (class 1) groups, we performed nearest-neighbor analysis using the signalto-noise statistic (m class 0 -m class 1)/(s class 0 + s class 1).
PTEN mutational analysis. We analyzed PTEN transcripts from RNA extracted from cryopreserved lymphoblast samples by direct bidirectional DNA sequencing. PCR amplified PTEN exons 1-9 in additional diagnostic DNA samples and in paired diagnostic and relapse DNA samples (obtained with informed consent; see Supplementary Methods online) were analyzed by digestion of DNA heteroduplexes with SURVEYOR (Cel I/II) nuclease (Transgenomic, Inc.), followed by fragment-size analysis with the Transgenomic WAVE Nucleic Acid High Sensitivity Fragment Analysis system (Transgenomic, Inc.), and verified by DNA sequencing.
OP9 cultures and expression analysis of DN3 cells. OP9-DL1 and OP9-control cells were generated from the OP9 bone marrow stromal cell line and maintained as described 46 . Fetal liver was harvested from timed-pregnant Rag2 -/-female mice on day 14 or 15 of gestation and single-cell suspensions were generated by disruption through a 40-mm nylon mesh screen using a syringe plunger. CD24 lo/-fetal liver cells, enriched for hematopoietic progenitor cells, were isolated by complement-mediated lysis of cells after incubation with CD24 antibody and subsequently cultured with OP9-DL1 cell monolayers for T lineage differentiation, as described 47 . All cultures were supplemented with 1 ng/ml mouse IL-7 and 5 ng/ml human recombinant FMS-like tyrosine kinase-3 ligand (Peprotech). CD44 -CD25 + GFP -DN3 cells were purified by cell sorting from day 7 cultures as described 47 and were further cultured for 1 or 2 d with either OP9-DL1 or OP9-control cells in the presence of cytokines, as above. CD45 + GFP -DN3 cells were sort-purified from cocultures to exclude OP9 cells before quantitative real-time PCR analysis.
Metabolic assays. We analyzed glucose uptake and oxidation in T-ALL cells treated with GSI (100 nM Compound E for 96 h) or vehicle-only (DMSO) control as previously described 48, 49 .
ChIP-on-chip and quantitative ChIP analysis. NOTCH1 (Val1744 antibody, Cell Signaling Technologies), HES1 (H-140 antibody, Santa Cruz Biotechnology) and MYC (N-262 antibody, Santa Cruz Biotechnology) immunoprecipitates and control genomic DNA of HPB-ALL cells were differentially labeled with Cy3 and Cy5 and hybridized to the Agilent Proximal Promoter Arrays following standard procedures. To analyze the binding ratios for probes located in the PTEN proximal promoter, we used the Chip Analytics 1.1 software (Agilent Technologies) and the UCSC Genome Browser. We performed realtime PCR (using ACTB genomic sequence levels as a loading control) to analyze ChIP enrichment of PTEN promoter sequences (-1492 to -1343 bp; -612 to -445 bp, and +118 to +278 bp from the transcription initiation site) in control genomic DNA (used as reference) and in chromatin immunoprecipitates done with antibodies to HES1 and MYC (see above antibodies) and IgG (negative control).
Overexpression of the Akt1 gene in Drosophila. The Gene Search line GS1D233C was isolated in a gain-of-expression genetic screen aimed at identifying genes that interact with the Notch pathway and that influence growth and tumorigenesis 34 . Genomic DNA flanking the P-element insertion in the GS1D233C was recovered by inverse PCR (http://www.fruitfly.org/about/ methods) and sequenced. A BLAST search with each sequence showed perfect matches to the Akt1 gene at the interval 89B6 (chromosome 3R, position 11925492-11925493) ( Supplementary Fig. 6a ). The GS P-element lines allow Gal4-dependent inducible expression of sequences flanking the insertion site of the GS element in both directions. Reverse-transcriptase PCR confirmed that transcription of the Akt1 gene is induced in the GS1D233C line in response to Gal4 treatment (data not shown).
Accession code. Microarray data are available in the GEO database (accession number GSE5682).
Note: Supplementary information is available on the Nature Medicine website.
